Reports Q3 revenue $39.8M, consensus $37.83M. “Our third quarter results reflect acceleration across every key dimension of OJEMDA’s performance and growing confidence among prescribers as we continue to build the case for second-line standard-of-care through execution and additional data readouts,” said Jeremy Bender, chief executive officer of Day One. “Combined with steady pipeline progress, we are well positioned to deliver sustainable growth for shareholders while we continue our mission to bring meaningful therapies to patients.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals, Inc. (DAWN) Q3 Earnings Cheat Sheet
- Day One Biopharmaceuticals’ Phase 3 Trial: A Potential Game Changer in Pediatric Glioma Treatment
- Day One Biopharmaceuticals Advances Cancer Treatment with DAY301 Study
- Day One Biopharmaceuticals Advances Pediatric Cancer Study with Promising Drug Tovorafenib
- Day One Biopharmaceuticals Reprices Stock Options for Retention